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the procedural success rate will be much higher than at 
present and the need for emergency surgery minimized. 
In these initial cases, we l used device sizes twice the 
balloon-sized diameter. 2 With experience, we have deter- 
mined that we can successfully use ratios between 1.2 and 
1.5, and, so long as the conjoint suture ring diameter 2 is as 
large as the anatomic diameter of the ASD, residual 
shunts are uncommon. The transient complete heart block 
(which did not require temporary pacing) was probably 
related to the large-sized evice used. 
Percutaneous closure of ASDs in human beings, who 
have thin compliant atrial septa and great variability of the 
size and position of the defects, is more difficult than the 
closure of experimentally created circular defects in the 
thick muscular atrial septa of dogs. 2 This device is self- 
centering and hence the anatomic riteria for selection of 
suitable candidates for this device is being actively inves- 
tigated. 
Surgical closure is the "gold standard" for the closure of 
ASDs. All three patients who needed emergency surgery 
in the series reported by Agarwal, Ghosh, and Mittal 1 
were adults. In a surgical series of 166 adult patients with 
ASDs, Horvath and associates 3 reported an early mortal- 
ity rate of only 1.2% but a perioperative complication rate 
of 13%. The complications included arrhythmias necessi- 
tating cardioversion, reoperation for bleeding, air embo- 
lism, tamponade, congestive heart failure, cerebrovascular 
accident, transient ischemic attack, complete heart block, 
and respiratory failure. Obviously these two reports can- 
not be directly compared. In the next phase of the U.S. 
arm of the trials we will be formally comparing device 
closure and surgical closure in patients with identical entry 
criteria. 
We hope that with greater experience in the use of this 
device, careful ong-term follow-up, and comparison with 
surgical closure in a structured clinical trial, we will be 
able to determine the role of this new investigational 
device for the percutaneous closure of ASDs. 
Gladwin S. Das, MD 
Cardiovascular Division 
University of Minnesota Hospital and Clinic 
Minneapolis, MN 55455 
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Reply to the Editor." 
The response of Dr. Das has aptly focused on the 
current deficiencies of atrial septal defect (ASD) closure 
devices and the limitations of extrapolating data from 
animal trials to therapeutic use in human beings. It was in 
this perspective that we proposed the currently relevant 
indications for the use of ASD closure devices. We shall 
not play Nostradamus. When Dr. Das's newer trial with a 
lower device/defect ratio and new retrieval system be- 
comes reproducibly effective, it may change the therapeu- 
tic approach to closure of ASDs. 
Probal K. Ghosh, MCh, FRCSE 
Surendra K. Agarwal, MCh 
Pramod K. Mittal, MCh 
Department of Cardiovascular and Thoracic Surgery 
Sanjay Gandhi PG Institute of Medical Science 
Lucknow 226 014, India 
12/8/78554 
Purulent pericarditis 
To the Editor: 
We are very interested in the article by Mann-Segal and 
associates, 1 concerning successful treatment of purulent 
pericarditis by irrigation of fibrinolytics, and we fully 
support his technique. We 2 previously reported the use of 
intrapericardial urokinase to dissolve pericardial fibrin 
layers in three patients, and the drug was well tolerated in 
these patients. Mann-Segal did not mention laboratory 
tests in his report; in our patients no changes occurred 
either in hemodynamic or in coagulation parameters 
during the period of intrapericardial fibrinolytic therapy. 
Our safety measures included echocardiography during 
instillation to detect iatrogenic right heart compression 
and warming of the irrigation fluid to prevent arrhythmias. 
We used urokinase for the lysis of pericardial fibrin 
deposits because urokinase has equal fibrinolytic potency 
but less antigenic potency than streptokinase. 3 The effi- 
cacy of urokinase in dissolving extravascular fibrin has 
been demonstrated especially in the pleural cavity by 
intrapleural administrationJ '5 
Fibrinolytic pericardial irrigation with urokinase as well 
as streptokinase seems to be a promising treatment of 
exudative fibrinous pericarditis, which can prevent con- 
strictive pericarditis without surgical intervention. The 
ideal dose and treatment regimen, however, remain to be 
defined. 
W.-B. Winkler, MD 
R. Karnik, MD 
Z Slany, MD 
Department of Internal Medicine II 
Krankenanstalt Rudolfstiftung 
A-1030 Wien, Austria 
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To the Editor." 
We thank Drs. Winkler, Karnik, and Slany for their 
interest in our work and are gratified by the increasing 
awareness of the role of fibrinolytic irrigation therapy in 
purulent pericarditis. With regard to their specific queries, 
no echocardiograms were performed uring pericardial 
irrigation. Serial echocardiograms over the period did, 
however, demonstrate a gradual diminution in the size of 
the loculated collections until they disappeared entirely. 
The alterations in left ventricular function as indicated by 
echocardiography and clinical evidence were entirely ben- 
eficial, and no hemodynamic compromise occurred. No 
coagulopathies or arrhythmias developed during the 
course of treatment. 
We agree that urokinase does have a theoretic advan- 
tage over streptokinase in that it is nonantigenic. Uroki- 
nase is far more expensive than streptokinase and is 
currently unavailable in Melbourne public hospitals. In 
addition, we are unaware of a commercially available 
combination of urokinase/streptodornase or streptodor- 
nase alone that could be added to urokinase. Strepto- 
dornase is advantageous in lavage therapy of loculated 
purulent pericarditis because it accelerates the depoly- 
merization of desoxyribose nucleoprotein, thereby lique- 
fying the viscous component of pus. As such, it can work 
synergistically with fibrinolytics, whether streptokinase or
urokinase, to facilitate drainage. It should be noted that 
streptodornase, like streptokinase, is antigenic. 
To date, all documentation regarding the treatment of 
purulent pericarditis with proteolytic and fibrinolytic en- 
zyme lavage has involved small series of patients. Forma- 
tion of antienzymes has not been documented in this 
context. Only a large prospective randomized trial will 
determine the efficacy of adding antibiotics to the lavage 
solution and the relative benefits and risks of adding 
streptodornase to urokinase or using urokinase instead of 
commercially available streptokinase/streptodornase. Our 
good fortune in seeing a decreased incidence of this 
disease over the years also means that such a study would 
have to be multicentered to obtain the numbers required 
to achieve statistically significant results. 
Until now all reported cases have been from groups that 
have developed their own fibrinolytic regimen de novo. 
We hope that the growing awareness of fibrinolytic ther- 
apy in purulent pericarditis will provide treatment options 
for clinicians without he need for further empiric trials in 
isolation from the published literature. 
Daniel D. M. Mann-Segal, MBBS 
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Bruce Jones, MBBS, FRACS 
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